Dr Geoffrey Nichol joins Ikaria

pharmafile | June 22, 2010 | Appointment | Research and Development Ikaria, appointment, research and development 

US biotherapeutics company Ikaria has appointed Dr Geoffrey Nichol chief medical officer, with responsibility for its late-stage drug development activies.

“We are delighted to welcome Geoff, who will leverage his extensive experience in driving our late-stage assets forward,” commented Daniel Tasse, Ikaria’s chairman and chief executive.

“We believe he can help us achieve our vision of becoming a leader in critical care by driving the commercialisation process of our two late-stage product candidates, as well as the FDA approval process for the additional indications we are pursuing for our marketed product Inomax.”

Dr Nichol has over 20 years of experience in the pharmaceutical industry and joins Ikaria from Medarex, where he was senior VP of product development.

Prior to this he held several leadership positions at Novartis Pharmaceuticals, and began his industry career at SmithKline Beecham Pharmaceuticals.

Related Content

sarah_mcdonald

Myeloma UK reveals new Director of Research appointment

UK non-profit organisation Myeloma UK has selected Sarah McDonald as its new Director of Research, …

white_and_ford

Abbott CEO to step down after 21 years

After more than two decades at the head of the company, it has emerged that …

funk

Lonza CEO to step down in 2020

It has been announced that Marc Funk, Chief Executive Officer at Lonza, is set to …

Latest content